HI
MRNA icon

Humankind Investments’s Moderna MRNA Stock Holding History

Humankind Investments’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,704
Closed -$251K – 116
2025
Q3 		$251K Sell
9,704
-913
-9% -$25.5K 0.06% 130
2025
Q2 		$293K Sell
10,617
-4,989
-32% -$131K 0.07% 110
2025
Q1 		$442K Buy
15,606
+1,179
+8% +$41.8K 0.11% 95
2024
Q4 		$600K Buy
14,427
+8,638
+149% +$413K 0.15% 74
2024
Q3 		$387K Buy
5,789
+2,206
+62% +$203K 0.14% 94
2024
Q2 		$425K Sell
3,583
-3,440
-49% -$435K 0.11% 93
2024
Q1 		$748K Sell
7,023
-613
-8% -$61.8K 0.2% 60
2023
Q4 		$759K Buy
7,636
+1,882
+33% +$158K 0.23% 55
2023
Q3 		$594K Buy
5,754
+1,055
+22% +$118K 0.25% 53
2023
Q2 		$571K Buy
4,699
+2,533
+117% +$338K 0.22% 58
2023
Q1 		$333K Buy
2,166
+215
+11% +$35.5K 0.14% 83
2022
Q4 		$350K Sell
1,951
-491
-20% -$80.3K 0.15% 84
2022
Q3 		$289K Buy
2,442
+216
+10% +$32.8K 0.14% 82
2022
Q2 		$318K Sell
2,226
-33
-1% -$4.72K 0.15% 78
2022
Q1 		$389K Buy
2,259
+1,081
+92% +$182K 0.16% 78
2021
Q4 		$299K Buy
1,178
+438
+59% +$128K 0.38% 78
2021
Q3 		$285K Sell
740
-336
-31% -$124K 0.43% 74
2021
Q2 		$253K Buy
+1,076
New +$192K 0.45% 70

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Humankind Investments's MRNA Position: Q4 2025 in Review

Humankind Investments sold out of Moderna (MRNA) in Q4 2025, closing a stake of 9,704 shares — an estimated $251K sold.

Humankind Investments first reported a position in MRNA in Q2 2021 and held it in 18 quarters. The position peaked at $759K in Q4 2023. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • Humankind Investments reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
  • Humankind Investments sold 9,704 Moderna shares in Q4 2025, an estimated $251K.
  • Humankind Investments first reported a position in Moderna in Q2 2021 and held it in 18 quarters.
  • Humankind Investments's Moderna position peaked at $759K in Q4 2023.
  • 672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Humankind Investments's 13F filing for Q4 2025, filed 17 Feb 2026.